Amgen's 'watershed' lung cancer drug nabs FDA nod in deadly, tough-to-treat form of the disease
Seven months after Amgen’s chief medical officer referred to trial results for the company's investigational lung cancer immunotherapy as a “watershed moment,” the FDA has signed off on Imdelltra (tarlatamab) to treat patients with extensive-stage …